The China Cardiac Assist Device Interventional landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2021-2026)
The China Cardiac Assist Device report is the first-ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Cardiology, and Cardiac surgery departments from Level 2 and Level 3 hospitals in China.
The report covers:
Cardiac assist device interventional procedures: bridge-to-device, bridge-to-recovery, and destination therapy
Interventional devices: biventricular assist devices, left ventricular assist devices, and right ventricular assist devices
Procedure trends: stages of the disease, by performing departments, by route of access used for the intervention, and type of interventions
Insights on hospital structure and utilization, physician treatment selection criteria, current and upcoming policies for diagnosis and treatment, and payer coverage are delved into.
Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.
Future trends such as the development of percutaneous ventricular assist devices for high-risk percutaneous coronary interventions are covered. Third generation LVAD with centrifugal flow magnetically levitated to treat end-stage heart failure being developed by Chinese companies to compete with the overseas MNCs will be a potential game-changer to watch out for in the growing cardiac assist device interventional devices market.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as CH-Biomedical receiving NMPA for their LVAD device; domestically developed total artificial heart developed by TEDA International Cardiovascular Hospital being approved, are covered in the report
What’s in it for you?
This report will help mechanical circulatory support device companies understand the Cardiac assist devices landscape, procedural and technology trends, the brand perception, in China.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the Cardiac assist devices market.
The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model. REPORT COST: 5,000 USD Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.